The DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
PD-1 and its ligands are important immune checkpoints in cancer
Open accessAbstract
// Yinan Dong 1 , Qian Sun 1 and Xinwei Zhang 1 1 Cell Immunology Lab, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Key Laboratory of “Cancer Prevention and therapy”, Key Laboratory of Immunology and Cancer Biotherapy, Tianjin, China Correspondence to: Xinwei Zhang, email: // Keywords : PD-1, PD-L1, PD-L2, T cell anergy, immune checkpoint blockade Received : April 14, 2016 Accepted : November 21, 2016 Published : December 10, 2016 Abstract Checkpoint programmed death-1 (PD-1)/programmed cell death ligands (PD-Ls) have been identified as negative immunoregulatory molecules that promote immune evasion of tumor cells. The interaction of PD-1 and PD-Ls inhibits the function of T cells and tumor-infiltrating lymphocytes (TIL) while increasing the function of immunosuppressive regulatory T cells (Tregs). This condition causes the tumor cells to evade immune response. Thus, the blockade of PD-1/PD-L1 enhances anti-tumor immunity by reducing the number and/or the suppressive activity of Tregs and by restoring the activity of effector T cells. Furthermore, some monoclonal antibodies blockading PD-1/PD-Ls axis have achieved good effect and received Food and Drug Administration approval. The role of PD-1/PD-Ls in tumors has been well studied, but little is known on the mechanism by which PD-1 blocks T-cell activation. In this study, we provide a brief overview on the discovery and regulatory mechanism of PD-1 and PD-L1 dysregulation in tumors, as well as the function and signaling pathway of PD-1 and its ligands; their roles in tumor evasion and clinical treatment were also studied.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Complete or partial response were showed in 17 patients [136].”
BackgroundPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 1×
“Several studies on Abs blockade of the PD-1 receptor (nivolumab, MK3475, or combination of nivolumab with the anti-CTLA4 checkpoint inhibitor ipilimumab) have improved survival profiles and acquired high response rates in several solid tumors [18-22].”
BackgroundSelf-citationRestoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Dong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
The PD‐1 pathway in tolerance and autoimmunity
Francisco, L. M., Sage, P. T., & Sharpe, A. H. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00923.x · Cited by 2,300
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
Francisco, L. M., Salinas, V. H., Brown, K. E., Vanguri, V. K., Freeman, G. J., Kuchroo, V. K., & Sharpe, A. H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090847 · Cited by 2,079
A family of cytokine-inducible inhibitors of signalling
Starr, R., Willson, T. A., Viney, E. M., Murray, L. J. L., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A., et al. (1997) · Nature · doi:10.1038/43206 · Cited by 2,066
CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms
Parry, R. V., Chemnitz, J. M., Frauwirth, K. A., Lanfranco, A. R., Braunstein, I., Kobayashi, S. V., Linsley, P. S., Thompson, C. B., & Riley, J. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.21.9543-9553.2005 · Cited by 1,931
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Ahmadzadeh, M., Johnson, L. A., Heemskerk, B., Wunderlich, J. R., Dudley, M. E., White, D. E., & Rosenberg, S. A. (2009) · Blood · doi:10.1182/blood-2008-12-195792 · Cited by 1,766
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes
Agata, Y., Kawasaki, A., Nishimura, H., Ishida, Y., Tsubat, T., Yagita, H., & Honjo, T. (1996) · International Immunology · doi:10.1093/intimm/8.5.765 · Cited by 1,589
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2012) · Current Opinion in Immunology · doi:10.1016/j.coi.2011.12.009 · Cited by 1,329
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
Green, M. R., Monti, S., Rodig, S. J., Juszczynski, P., Currie, T., O'Donnell, E., Chapuy, B., Takeyama, K., Neuberg, D., Golub, T. R., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282780 · Cited by 1,305
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,231
VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20140559 · Cited by 1,179
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
(2015) · New England Journal of Medicine · doi:10.1056/nejmc1509660 · Cited by 872
Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., Beck, A., Miller, A., Tsuji, T., Eppolito, C., Qian, F., Lele, S., Shrikant, P., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1003345107 · Cited by 859
Okazaki, T., Maeda, A., Nishimura, H., Kurosaki, T., & Honjo, T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231486598 · Cited by 848
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Ohaegbulam, K. C., Assal, A., Lazar-Molnar, E., Yao, Y., & Zang, X. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.009 · Cited by 843
Cytokine Signaling Modules in Inflammatory Responses
O'Shea, J. J., & Murray, P. J. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.002 · Cited by 818
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Chauvin, J.-M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 784
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · cited 9×
“Binding of HIF-1α to a transcriptionally active hypoxiaresponse elements (HREs), HRE-4 and HRE-1, at two different HRE sites in the PD-L1 proximal promoter in hypoxic MSC-1 cells is comparable with their binding to an established HRE in VEGF, lactate dehydrogenase A (LDHA), and Glut1 genes [77].”
BackgroundInfluentialEnhancing SIV-specific immunity in vivo by PD-1 blockade
Velu, V., Titanji, K., Zhu, B., Husain, S., Pladevega, A., Lai, L., Vanderford, T. H., Chennareddi, L., Silvestri, G., Freeman, G. J., et al. (2009) · Nature · doi:10.1038/nature07662 · Cited by 771
IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., & Mandai, M. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.101 · Cited by 725
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 669
Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & Tokura, Y. (2010) · Cancer · doi:10.1002/cncr.24899 · Cited by 667
Wang, C., Thudium, K. B., Han, M., Wang, X.-T., Huang, H., Feingersh, D., Garcia, C., Wu, Y., Kuhne, M., Srinivasan, M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0040 · Cited by 601
Thompson, R. H., Dong, H., Lohse, C. M., Leibovich, B. C., Blute, M. L., Cheville, J. C., & Kwon, E. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2599 · Cited by 569
Sunshine, J., & Taube, J. M. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.011 · Cited by 560
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
Kwok, G., Yau, T. C. C., Chiu, J. W., Tse, E., & Kwong, Y.-L. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1199310 · Cited by 498
Kao, C., Oestreich, K. J., Paley, M. A., Crawford, A., Angelosanto, J. M., Ali, M.-A. A., Intlekofer, A. M., Boss, J. M., Reiner, S. L., Weinmann, A. S., et al. (2011) · Nature Immunology · doi:10.1038/ni.2046 · Cited by 484
Role of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444 · cited 2×
“PD-L2 is expressed mainly on antigenpresenting cells (APCs), including macrophages and myeloid DCs, and non-hematopoietic tissues, such as the lung [62, 63].”
BackgroundArmand, P., Nagler, A., Weller, E. A., Devine, S. M., Avigan, D. E., Chen, Y.-B., Kaminski, M. S., Holland, H. K., Winter, J. N., Mason, J. R., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.3685 · Cited by 440
Ota, K., Azuma, K., Kawahara, A., Hattori, S., Iwama, E., Tanizaki, J., Harada, T., Matsumoto, K., Takayama, K., Takamori, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0016 · Cited by 435
Structural and Functional Analysis of the Costimulatory Receptor Programmed Death-1
Zhang, X., Schwartz, J.-C. D., Guo, X., Bhatia, S., Cao, E., Chen, L., Zhang, Z.-Y., Edidin, M. A., Nathenson, S. G., & Almo, S. C. (2004) · Immunity · doi:10.1016/s1074-7613(04)00051-2 · Cited by 410
Self-citationPredictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 401
Indoleamine 2,3-Dioxygenase Expression in Human Cancers: Clinical and Immunologic Perspectives
Godin-Ethier, J., Hanafi, L.-A., Piccirillo, C. A., & Lapointe, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1331 · Cited by 392
The PD-1/PD-Ls pathway and autoimmune diseases
Dai, S., Jia, R., Zhang, X., Fang, Q., & Huang, L. (2014) · Cellular Immunology · doi:10.1016/j.cellimm.2014.05.006 · Cited by 354
Self-citationTherapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
Philips, G. K., & Atkins, M. (2015) · International Immunology · doi:10.1093/intimm/dxu095 · Cited by 335
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M., Avramis, E., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 334
Xiao, Y., Yu, S., Zhu, B., Bedoret, D., Bu, X., Francisco, L. M., Hua, P., Duke-Cohan, J. S., Umetsu, D. T., Sharpe, A. H., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130790 · Cited by 321
Dulos, J., Carven, G. J., van Boxtel, S. J., Evers, S., Driessen-Engels, L. J. A., Hobo, W., Gorecka, M. A., de Haan, A. F. J., Mulders, P., Punt, C. J. A., et al. (2012) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318247a4e7 · Cited by 316
Ritprajak, P., & Azuma, M. (2015) · Oral Oncology · doi:10.1016/j.oraloncology.2014.11.014 · Cited by 314
Huang, R.-Y., Eppolito, C., Lele, S., Shrikant, P., Matsuzaki, J., & Odunsi, K. (2015) · Oncotarget · doi:10.18632/oncotarget.4751 · Cited by 308
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008824 · Cited by 307
Strength of PD-1 signaling differentially affects T-cell effector functions
Wei, F., Zhong, S., Ma, Z., Kong, H., Medvec, A., Ahmed, R., Freeman, G. J., Krogsgaard, M., & Riley, J. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305394110 · Cited by 304
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297
Bellmunt, J., Mullane, S. A., Werner, L., Fay, A. P., Callea, M., Leow, J. J., Taplin, M. E., Choueiri, T. K., Hodi, F. S., Freeman, G. J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv009 · Cited by 276
Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity
Gianchecchi, E., Delfino, D. V., & Fierabracci, A. (2013) · Autoimmunity Reviews · doi:10.1016/j.autrev.2013.05.003 · Cited by 270
Programmed death-1 pathway in cancer and autoimmunity
Pedoeem, A., Azoulay-Alfaguter, I., Strazza, M., Silverman, G. J., & Mor, A. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.04.010 · Cited by 268
Structure and Chromosomal Localization of the Human PD-1 Gene (PDCD1)
Shinohara, T., Taniwaki, M., Ishida, Y., Kawaichi, M., & Honjo, T. (1994) · Genomics · doi:10.1006/geno.1994.1562 · Cited by 253
Kim, J. W., Nam, K. H., Ahn, S.-H., Park, D. J., Kim, H.-H., Kim, S. H., Chang, H., Lee, J.-O., Kim, Y. J., Lee, H. S., et al. (2016) · Gastric Cancer · doi:10.1007/s10120-014-0440-5 · Cited by 250
Li, J., Jie, H.-B., Lei, Y., Gildener-Leapman, N., Trivedi, S., Green, T., Kane, L. P., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1215 · Cited by 246
T‐cell tolerance or function is determined by combinatorial costimulatory signals
Nurieva, R., Thomas, S., Nguyen, T., Martin‐Orozco, N., Wang, Y., Kaja, M., Yu, X., & Dong, C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601146 · Cited by 245
PD-1-Mediated Suppression of IL-2 Production Induces CD8+ T Cell Anergy In Vivo
Chikuma, S., Terawaki, S., Hayashi, T., Nabeshima, R., Yoshida, T., Shibayama, S., Okazaki, T., & Honjo, T. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900080 · Cited by 231
Calcium signalling and cell-fate choice in B cells
Scharenberg, A. M., Humphries, L. A., & Rawlings, D. J. (2007) · Nature Reviews Immunology · doi:10.1038/nri2172 · Cited by 225
Ghebeh, H., Barhoush, E., Tulbah, A., Elkum, N., Al-Tweigeri, T., & Dermime, S. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-57 · Cited by 211
Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
Swaika, A., Hammond, W. A., & Joseph, R. W. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.02.009 · Cited by 201
Enhanced Tumor Eradication by Combining CTLA-4 or PD-1 Blockade With CpG Therapy
Mangsbo, S. M., Sandin, L. C., Anger, K., Korman, A. J., Loskog, A., & Tötterman, T. H. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181c01fcb · Cited by 198
Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
Boussiotis, V. A., Chatterjee, P., & Li, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000059 · Cited by 185
PD-1 blockade therapy in renal cell carcinoma: Current studies and future promises
Massari, F., Santoni, M., Ciccarese, C., Santini, D., Alfieri, S., Martignoni, G., Brunelli, M., Piva, F., Berardi, R., Montironi, R., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.013 · Cited by 180
Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation
Sanmamed, M. F., & Chen, L. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000061 · Cited by 178
Austin, J. W., Lu, P., Majumder, P., Ahmed, R., & Boss, J. M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1302750 · Cited by 167
NF-κB Regulates PD-1 Expression in Macrophages
Bally, A. P. R., Lu, P., Tang, Y., Austin, J. W., Scharer, C. D., Ahmed, R., & Boss, J. M. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402550 · Cited by 166
Lu, P., Youngblood, B., Austin, J. W., Mohammed, A. U. R., Butler, R., Ahmed, R., & Boss, J. M. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20130208 · Cited by 165
Chen, J., Feng, Y., Lu, L., Wang, H., Dai, L., Li, Y., & Zhang, P. (2012) · Immunobiology · doi:10.1016/j.imbio.2011.10.016 · Cited by 164
Balan, M., y Teran, E. M., Waaga-Gasser, A. M., Gasser, M., Choueiri, T. K., Freeman, G. J., & Pal, S. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.612689 · Cited by 158
The roles of Dok family adapters in immunoreceptor signaling
Mashima, R., Hishida, Y., Tezuka, T., & Yamanashi, Y. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00844.x · Cited by 154
Inhibitory receptors, ITIM sequences and phosphatases
Unkeless, J. C., & Jin, J. (1997) · Current Opinion in Immunology · doi:10.1016/s0952-7915(97)80079-9 · Cited by 152
PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A
Patsoukis, N., Sari, D., & Boussiotis, V. A. (2012) · Cell Cycle · doi:10.4161/cc.22135 · Cited by 143
Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1
Xiao, G., Deng, A., Liu, H., Ge, G., & Liu, X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206370109 · Cited by 133
Liu, J., Kang, H. K., Raab, M., da Silva, A. J., Kraeft, S., & Rudd, C. E. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8779 · Cited by 132
Maine, C. J., Aziz, N. H. A., Chatterjee, J., Hayford, C., Brewig, N., Whilding, L. M., George, A. J. T., & Ghaem‐Maghami, S. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1503-x · Cited by 129
Chen, L., Sun, J., Wu, H., Zhou, S.-M., Tan, Y. Q., Tan, M., Shan, B.-E., Lu, B., & Zhang, X. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1017-3 · Cited by 125
Self-citationLázár‐Molnár, E., Gácser, A., Freeman, G. J., Almo, S. C., Nathenson, S. G., & Nosanchuk, J. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711918105 · Cited by 125
Zhang, Y., Kang, S., Shen, J., He, J., Jiang, L., Wang, W., Guo, Z., Peng, G., Chen, G., He, J., et al. (2015) · Medicine · doi:10.1097/md.0000000000000515 · Cited by 116
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway
Postow, M. A., & Momtaz, P. (2014) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s53163 · Cited by 114
Krönig, H., Kremmler, L., Haller, B., Englert, C., Peschel, C., Andreesen, R., & Blank, C. U. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12228 · Cited by 110
PD-1 regulates extrathymic regulatory T-cell differentiation
Chen, X., Fosco, D., Kline, D. E., Meng, L., Nishi, S., Savage, P. A., & Kline, J. (2014) · European Journal of Immunology · doi:10.1002/eji.201344423 · Cited by 107
Zheng, Y., Zha, Y., Driessens, G., Locke, F. L., & Gajewski, T. F. (2012) · The Journal of Experimental Medicine · doi:10.1084/jem.20120342 · Cited by 106
Yun, S., Vincelette, N. D., Green, M. R., Hendrickson, A. E. W., & Abraham, I. L. (2016) · Cancer Medicine · doi:10.1002/cam4.732 · Cited by 100
Stanciu, L. A., Bellettato, C. M., Laza‐Stanca, V., Coyle, A. J., Papi, A. A., & Johnston, S. L. (2006) · The Journal of Infectious Diseases · doi:10.1086/499275 · Cited by 99
PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
Ji, M. Q., Liu, Y., Li, Q., Li, X., Zhao, W., Zhang, H., Zhang, X., Jiang, J., & Wu, C. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-014-0373-0 · Cited by 96
Self-citationIncreased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer
Saito, H., Kuroda, H., Matsunaga, T., Osaki, T., & Ikeguchi, M. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23281 · Cited by 94
Marie‐Cardine, A., Hendricks-Taylor, L. R., Boerth, N. J., Zhao, H., Schraven, B. L., & Koretzky, G. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.40.25789 · Cited by 91
Shindo, Y., Yoshimura, K., Kuramasu, A., Watanabe, Y., Ito, H., Kondo, T., Oga, A., Ito, H., Yoshino, S., Hazama, S., et al. (2015) · PubMed · Cited by 82
Langer, C. J. (2014) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000059 · Cited by 78
Roles of LAG3 and EGR2 in regulatory T cells
Okamura, T., Fujio, K., Sumitomo, S., & Yamamoto, K. (2012) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2011-200588 · Cited by 77
Jandus, C., Bioley, G., Speiser, D. E., & Romero, P. J. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0507-4 · Cited by 76
Wang, S., Li, H., Li, B., Xie, T., Zhu, T., Sun, L., Ren, H., & Ye, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.05.016 · Cited by 70
Stork, B., Neumann, K., Goldbeck, I., Alers, S., Kähne, T., Naumann, M., Engelke, M., & Wienands, J. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601557 · Cited by 69
Lu, B., Chen, L., Liu, L., Zhu, Y., Wu, C., Jiang, J., & Zhang, X. (2011) · Immunologic Research · doi:10.1007/s12026-011-8227-9 · Cited by 67
Self-citationBu, M., Shen, Y., Seeger, W. L., An, S., Qi, R., Sanderson, J. A., & Cai, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-4237-x · Cited by 66
McPherson, R. C., Konkel, J. E., Prendergast, C. T., Thomson, J. P., Ottaviano, R., Leech, M. D., Kay, O., Zandee, S., Sweenie, C. H., Wraith, D. C., et al. (2014) · eLife · doi:10.7554/elife.03416 · Cited by 63
Li, C., Li, W., Xiao, J., Jiao, S., Teng, F., Xue, S., Zhang, C., Sheng, C., Leng, Q., Rudd, C. E., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404578 · Cited by 60
Expression of programmed death 1 is correlated with progression of osteosarcoma
Zheng, W., Xiao, H. P., Liu, H., & Zhou, Y. (2014) · Apmis · doi:10.1111/apm.12311 · Cited by 60
Prospects for targeting PD-1 and PD-L1 in various tumor types.
Kim, J. W., & Eder, J. P. (2014) · PubMed · Cited by 56
Zhao, S., Li, F., Leak, R. K., Chen, J., & Hu, X. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00271 · Cited by 53
Overcoming Tumor-Mediated Immunosuppression
Schlößer, H., Theurich, S., Shimabukuro‐Vornhagen, A., Holtick, U., Stippel, D. L., & von Bergwelt‐Baildon, M. (2014) · Immunotherapy · doi:10.2217/imt.14.58 · Cited by 49
Dok-3 plays a nonredundant role in negative regulation of B-cell activation
Ng, C.-H., Xu, S., & Lam, K. (2007) · Blood · doi:10.1182/blood-2006-10-055194 · Cited by 48
Blocking tumor escape in hematologic malignancies: The anti-PD-1 strategy
Bryan, L. J., & Gordon, L. I. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.09.004 · Cited by 46
Koh, Y. W., Jeon, Y. K., Yoon, D. H., Suh, C., & Huh, J. (2015) · Tumor Biology · doi:10.1007/s13277-015-4622-5 · Cited by 46
PD-1 induction through TCR activation is partially regulated by endogenous TGF-β
Rekik, R., Hmida, N. B., Hmid, A. B., Zamali, I., Kammoun, N., & Ahmed, M. B. (2014) · Cellular and Molecular Immunology · doi:10.1038/cmi.2014.104 · Cited by 45
Ellestad, K. K., Thangavelu, G., Ewen, C., Boon, L., & Anderson, C. C. (2014) · European Journal of Immunology · doi:10.1002/eji.201444688 · Cited by 45
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence
Tykodi, S. S. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s48443 · Cited by 44
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancer
Henick, B. S., Herbst, R. S., & Goldberg, S. B. (2014) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2014.955794 · Cited by 41
Liu, C., Jiang, J., Gao, L., Hu, X., Wang, F., Shen, Y., Yu, G., Zhao, Z., & Zhang, X. (2014) · International Journal of Genomics · doi:10.1155/2014/247637 · Cited by 36
Self-citationThe role of programmed cell death‐1 (PD‐1) and its ligands in pediatric cancer
van Dam, L. S., de Zwart, V., & Meyer‐Wentrup, F. A. G. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25284 · Cited by 35
A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice.
Hardy, B., Yampolski, I., Kovjazin, R., Galli, M., & Novogrodsky, A. (1994) · PubMed · Cited by 34
The immune cell transcription factor T-bet: A novel metabolic regulator
Stolarczyk, E., Lord, G. M., & Howard, J. K. (2014) · Adipocyte · doi:10.4161/adip.26220 · Cited by 32
Bishop, K. D., Harris, J. E., Mordes, J. P., Greiner, D. L., Rossini, A. A., Czech, M., & Phillips, N. E. (2009) · Cellular Immunology · doi:10.1016/j.cellimm.2009.01.008 · Cited by 30
Freeman-Keller, M., & Weber, J. S. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014551747 · Cited by 27
Ou, X., Xu, S., Li, Y.-F., & Lam, K. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400539111 · Cited by 27
Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced non-small cell lung cancer.
Rajan, A., & Gulley, J. L. (2014) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.09.02 · Cited by 20
Kan‐o, K., Matsumoto, K., Asai, Y., Fukuyama, S., Hamano, S., Seki, N., Nakanishi, Y., & Inoue, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.082 · Cited by 15
Shiner, E. K., Holbrook, B. C., & Alexander‐Miller, M. A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100175 · Cited by 15
Pembrolizumab Joins the Anti-PD-1 Armamentarium in the Treatment of Melanoma
Hersey, P., & Gowrishankar, K. (2015) · Future Oncology · doi:10.2217/fon.14.205 · Cited by 14
Genetic and Molecular Targets in Lymphoma: Implications for Prognosis and Treatment
Bachegowda, L., & Barta, S. K. (2014) · Future Oncology · doi:10.2217/fon.14.112 · Cited by 6
Qian, N., Gao, L., Dong, L., Liu, H., Fu, J., Meng, D., Gao, X., Zhang, J., Gao, Y., & Song, H. (2015) · Protein Expression and Purification · doi:10.1016/j.pep.2015.01.004 · Cited by 1
Cited by
Top 10 Challenges in Cancer Immunotherapy
Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Wang, D.-R., Wu, X.-L., & Sun, Y.-L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01136-2 · Cited by 501
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Barrueto, L., Caminero, F., Cash, L., Makris, C., Lamichhane, P., & Deshmukh, R. R. (2020) · Translational Oncology · doi:10.1016/j.tranon.2019.12.010 · Cited by 281
Cox, M., Kartikasari, A. E. R., Gorry, P. R., Flanagan, K. L., & Plebanski, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040351 · Cited by 30
Metadata
- Authors
- Dong, Y., Sun, Q., & Zhang, X.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-12-10
- Volume
- 8
- Issue
- 2
- Pages
- 2171-2186
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2561100838
- Cited by
- 334
- References
- 139
- FWCI
- 12.21
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.